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I
n the March issue of Diabetes, there is a very in-
teresting article by Jurczak et al. (1) about glucose
homeostasis and b-cell function in mice with a de-
letion in SGLT-2. There is also an accompanying
editorial by Ferrannini (2) that is appropriately laudatory
to the article but there are some extraordinary comments
including, “Collectively, these ﬁndings prove that reduced
SGLT-2 activity—whether genetically or experimentally
induced—is efﬁcacious and relatively safe ..” All of us are
entitled to our opinion. But the combined knowledge
obtained from humans with renal glycosuria, the clinical
trials with these drugs, and this transgenic mouse study
are important and intriguing but do not prove long-term
safety, especially in diabetic patients with kidney disease.
There are no safety studies in diabetic patients with
kidney disease. And there is certainly reason for concern
that patients with kidney disease (at any stage) may have
deleterious consequences being exposed to high glucose
levels in the renal tubules for years. Thus I have major safety
concerns about the long-term use of these new medications
in patients with diabetic kidney disease. At the very least the
risks to patients with diabetic kidney disease are unknown.
More concerning was the statement at the end of the
editorial that “No potential conﬂicts of interest relevant to
this article were reported.” A quick online search revealed
that Dr. Ferrannini is the ﬁrst author on a study using an
SGLT-2 inhibitor. This study was sponsored by the drug
company. Indeed, it is reference number 13 in the editorial.
In addition, there is an abstract in which Dr. Ferrannini is
the ﬁrst author in which another drug company’s SGLT-2
inhibitor is studied.
I have no problem at all with researchers expressing
their thoughts, ideas, and opinions, but it is extremely
important that potential conﬂicts be clearly stated.
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